These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 18443126

  • 1. Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.
    He Z, Qin L, Chen L, Peng N, You J, Chen X.
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2653-6. PubMed ID: 18443126
    [Abstract] [Full Text] [Related]

  • 2. Antiretroviral protease inhibitors potentiate chloroquine antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism.
    He Z, Chen L, You J, Qin L, Chen X.
    Exp Parasitol; 2009 Oct; 123(2):122-7. PubMed ID: 19538959
    [Abstract] [Full Text] [Related]

  • 3. Synergy of the antiretroviral protease inhibitor indinavir and chloroquine against malaria parasites in vitro and in vivo.
    Li X, He Z, Chen L, Li Y, Li Q, Zhao S, Tao Z, Hu W, Qin L, Chen X.
    Parasitol Res; 2011 Dec; 109(6):1519-24. PubMed ID: 21537980
    [Abstract] [Full Text] [Related]

  • 4. Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
    Skinner-Adams TS, Andrews KT, Melville L, McCarthy J, Gardiner DL.
    Antimicrob Agents Chemother; 2007 Feb; 51(2):759-62. PubMed ID: 17088482
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy.
    Choi H, Jeong SJ, Lee HS, Chin BS, Choi SH, Han SH, Kim MS, Kim CO, Choi JY, Song YG, Kim JM.
    J Korean Med Sci; 2008 Aug; 23(4):737-9. PubMed ID: 18756069
    [Abstract] [Full Text] [Related]

  • 8. Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
    Lopes SC, Blanco YC, Justo GZ, Nogueira PA, Rodrigues FL, Goelnitz U, Wunderlich G, Facchini G, Brocchi M, Duran N, Costa FT.
    Antimicrob Agents Chemother; 2009 May; 53(5):2149-52. PubMed ID: 19273690
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the sensitivity in vitro of Plasmodium falciparum and in vivo of Plasmodium chabaudi Malaria to various drugs and their combinations.
    Rahman NN.
    Med J Malaysia; 1997 Dec; 52(4):390-8. PubMed ID: 10968116
    [Abstract] [Full Text] [Related]

  • 10. Is the expression of genes encoding enzymes of glutathione (GSH) metabolism involved in chloroquine resistance in Plasmodium chabaudi parasites?
    Ferreira ID, Nogueira F, Borges ST, do Rosário VE, Cravo P.
    Mol Biochem Parasitol; 2004 Jul; 136(1):43-50. PubMed ID: 15138066
    [Abstract] [Full Text] [Related]

  • 11. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir.
    Manosuthi W, Sungkanuparph S, Ruxrungtham K, Prasithsirikul W, Athichathanabadi C, Tantisiriwat W, Bowonwatanuwong C, Chumpathat N, Chaovavanich A.
    J Acquir Immune Defic Syndr; 2008 Jan 01; 47(1):127-9. PubMed ID: 18156994
    [No Abstract] [Full Text] [Related]

  • 12. In vitro activity of antiretroviral drugs against Plasmodium falciparum.
    Nsanzabana C, Rosenthal PJ.
    Antimicrob Agents Chemother; 2011 Nov 01; 55(11):5073-7. PubMed ID: 21876053
    [Abstract] [Full Text] [Related]

  • 13. A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum.
    Burgess SJ, Selzer A, Kelly JX, Smilkstein MJ, Riscoe MK, Peyton DH.
    J Med Chem; 2006 Sep 07; 49(18):5623-5. PubMed ID: 16942036
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
    Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ.
    Antimicrob Agents Chemother; 2005 Jul 07; 49(7):2983-5. PubMed ID: 15980379
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
    Dam E, Lebel-Binay S, Rochas S, Thibaut L, Faudon JL, Thomas CM, Essioux L, Hill A, Schutz M, Clavel F.
    Antivir Ther; 2007 Jul 07; 12(3):371-80. PubMed ID: 17591027
    [Abstract] [Full Text] [Related]

  • 18. Gene synteny and chloroquine resistance in Plasmodium chabaudi.
    Hunt P, Martinelli A, Fawcett R, Carlton J, Carter R, Walliker D.
    Mol Biochem Parasitol; 2004 Aug 07; 136(2):157-64. PubMed ID: 15478795
    [Abstract] [Full Text] [Related]

  • 19. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
    Ford J, Boffito M, Maitland D, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A.
    J Antimicrob Chemother; 2006 Nov 07; 58(5):1009-16. PubMed ID: 16984898
    [Abstract] [Full Text] [Related]

  • 20. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E, Lopez RM, Diaz M, Pou L, Ruiz L, Falcó V, Crespo M, Azuaje C, Ruiz I, Ocaña I, Clotet B, Pahissa A.
    Antimicrob Agents Chemother; 2004 Nov 07; 48(11):4256-62. PubMed ID: 15504850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.